17-dimethylaminoethylamino-17-demethoxygeldanamycin

From WikiMD's Wellness Encyclopedia


17-Dimethylaminoethylamino-17-demethoxygeldanamycin[edit | edit source]

17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) is a semi-synthetic derivative of the natural product geldanamycin, which is an antibiotic originally isolated from the bacterium Streptomyces hygroscopicus. 17-DMAG is primarily studied for its potential use as an anticancer agent due to its ability to inhibit heat shock protein 90 (Hsp90), a molecular chaperone involved in the stabilization and function of many oncoproteins.

Mechanism of Action[edit | edit source]

17-DMAG functions as an inhibitor of Hsp90, a protein that assists in the proper folding and function of various client proteins, many of which are involved in cell signaling, cell cycle regulation, and apoptosis. By inhibiting Hsp90, 17-DMAG causes the degradation of these client proteins, leading to the disruption of multiple signaling pathways that are crucial for the growth and survival of cancer cells.

Hsp90 inhibitors like 17-DMAG bind to the ATP-binding pocket of Hsp90, preventing its ATPase activity, which is essential for its chaperone function. This results in the ubiquitination and proteasomal degradation of client proteins, ultimately leading to cell death in cancer cells.

Clinical Applications[edit | edit source]

17-DMAG has been investigated in various clinical trials for its efficacy against different types of cancer, including breast cancer, lung cancer, and leukemia. Its water solubility and oral bioavailability make it a promising candidate compared to other geldanamycin derivatives, which often have poor solubility and require intravenous administration.

Side Effects and Toxicity[edit | edit source]

As with many anticancer agents, 17-DMAG can cause a range of side effects. Commonly reported adverse effects include gastrointestinal disturbances, hepatotoxicity, and myelosuppression. The development of less toxic and more selective Hsp90 inhibitors remains an area of active research.

Research and Development[edit | edit source]

Ongoing research is focused on improving the selectivity and reducing the toxicity of 17-DMAG and other Hsp90 inhibitors. Combination therapies with other anticancer agents are also being explored to enhance the therapeutic efficacy of 17-DMAG.

Also see[edit | edit source]


CaptionSynonyms
17-dimethylaminoethylamino-17-demethoxygeldanamycin
Drug Information
Image 250
Identifiers


DrugBank


ChEBI


Chemical Data



WikiMD
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

Contributors: Bonnu, Prab R. Tumpati, MD